This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
NCT03207750
Completed
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
12/07/2020
Locations: GSK Investigational Site, Kaysville, Utah +7 locations
Conditions: Rotavirus Infection, Rotavirus Vaccines
Register for Updates
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
NCT03314662
Completed
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/20/2020
Locations: Advanced Clinical Research, West Jordan, Utah
Conditions: Influenza, Human
Register for Updates
BARDA Securing Anthrax Immunity For the Elderly
NCT03518125
Completed
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2020
Locations: JBR Clinical Research, Salt Lake City, Utah
Conditions: Anthrax
Register for Updates
LT Vaccine Patch Self-Administration Study
NCT00565461
Completed
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered vaccination.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/17/2020
Locations: Jean Brown Research, Salt Lake City, Utah
Conditions: Prevention of Travelers' Diarrhea
Register for Updates
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
NCT02270944
Completed
The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulation of GBS Trivalent Vaccine, administered in non-pregnant and pregnant women in the clinical development program to date.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
11/19/2019
Locations: GSK Investigational Site, Salt Lake City, Utah
Conditions: Infections, Streptococcal, Streptococcal Infections
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
NCT02117934
Completed
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/18/2019
Locations: Radiant Research, Murray, Utah
Conditions: Healthy
Register for Updates
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
NCT00224484
Completed
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Gender:
FEMALE
Ages:
Between 10 years and 17 years
Trial Updated:
01/03/2019
Locations: GSK Investigational Site, Magna, Utah +5 locations
Conditions: Herpes Simplex
Register for Updates
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
NCT02914275
Completed
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
12/30/2018
Locations: Site 395, Layton, Utah +6 locations
Conditions: Influenza, Human
Register for Updates
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Completed
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
09/10/2018
Locations: Not set, Layton, Utah +2 locations
Conditions: Meningococcal Disease, Meningococcal Meningitis
Register for Updates
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
NCT00614614
Completed
The purpose of the study is to characterize the immunogenicity \& safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Layton, Utah +7 locations
Conditions: Infections, Meningococcal
Register for Updates
HerpeVac Trial for Young Women
NCT00057330
Completed
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evalua... Read More
Gender:
FEMALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/26/2018
Locations: GSK Investigational Site, Salt Lake City, Utah +1 locations
Conditions: Herpes Simplex Infection
Register for Updates
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
NCT01230957
Completed
This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility. Primary Objectives: * To describe the safety profile of subjects in each of the study groups. * To describe the immune responses elicited by toxoid A and toxoid B of subjects in each of the study groups. Observational Objective: * To describe the occurrence of first-tim... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
07/13/2018
Locations: Not set, Salt Lake City, Utah +2 locations
Conditions: Clostridium Difficile Infection, Diarrhea
Register for Updates